CANF
Can Fite Biopharma Ltd ADR
AMEX: CANF · HEALTHCARE · BIOTECHNOLOGY
$3.39
-2.22% today
Updated 2026-06-05
Market cap
$6.77M
P/E ratio
—
P/S ratio
16.45x
EPS (TTM)
$-10.75
Dividend yield
—
52W range
$3 – $23
Volume
0.6M
WallStSmart proprietary scores
20
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F6.5
Quality
B2.5
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
-27.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$5.00
+47.49%
12-Month target
—
—
Intrinsic (DCF)
$11.03
Margin of safety
+60.11%
0 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ 60.11% below intrinsic value
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -27.66 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-9.02M
- Revenue declining -43.30% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $810000.00 | $743000.00 | $674000.00 | $408212.00 | $405000.00 |
| Net income | $-10.24M | $-7.63M | $-7.88M | $-9.91M | $-9.91M |
| EPS | — | — | — | — | $-10.75 |
| Free cash flow | $-10.81M | $-8.44M | $-7.64M | $-9.02M | $-9.02M |
| Profit margin | -1,263.70% | -1,027.46% | -1,169.14% | -2,426.67% | — |
Peer comparison
Smart narrative
Can Fite Biopharma Ltd ADR trades at $3.39. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -27.66, it sits in the distress. TTM revenue stands at $405000.00. Our DCF model estimates intrinsic value at $11.03.
Frequently asked questions
What is Can Fite Biopharma Ltd ADR's stock price?
Can Fite Biopharma Ltd ADR (CANF) trades at $3.39, on a P/S of 16.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Can Fite Biopharma Ltd ADR overvalued?
Can Fite Biopharma Ltd ADR carries a Smart Value Score of 20/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $11.03 versus the $3.39 price, a 60.1% margin of safety on a cash flow basis.
What is the price target of Can Fite Biopharma Ltd ADR (CANF)?
The 12-month analyst consensus target is $5.00, about 47.5% above the current $3.39. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Can Fite Biopharma Ltd ADR (CANF)?
Our DCF model estimates intrinsic value at $11.03, a +60.1% margin of safety versus today's $3.39. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Can Fite Biopharma Ltd ADR's revenue?
Can Fite Biopharma Ltd ADR's trailing twelve-month revenue is $405000.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Can Fite Biopharma Ltd ADR's Altman Z-Score is -27.66, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeAMEX
CurrencyUSD
Quick metrics
P/S ratio16.45x
ROE-157.35%
Beta0.03
50D MA$3.18
200D MA$6.48
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—